10/28/2026
Your heart, kidneys and metabolism are connected. Your healthcare should be, too.
Cardiovascular–kidney–metabolic—or CKM—care considers how cardiovascular disease, kidney disease, diabetes, obesity and other metabolic risk factors can overlap.
Two medication classes receiving significant attention include:
- GLP-1–based medicines: May support blood-sugar control and weight management, while certain medications may reduce cardiovascular risk in eligible patients.
- SGLT2 inhibitors: May help protect the heart and kidneys in selected patients, including some people with heart failure or chronic kidney disease who do not have diabetes.
These medication classes work differently. Benefits and approved uses vary, and not every patient needs or qualifies for either therapy.
Call SARC Cardiovascular and Vein Center at 870-534-2900 to schedule a cardiovascular evaluation and discuss your individual risk factors.
This information is educational and is not individual medical advice. Never start, stop or change medication without guidance from your healthcare provider.
Clinical reference: 2026 cardiovascular–kidney–metabolic syndrome guidance from the AHA and ACC.